Supernus Pharmaceuticals SUPN Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's unrealized losses on investments (before tax)?
- Supernus Pharmaceuticals (SUPN) reported unrealized losses on investments (before tax) of $254K in Q1 2026.
- How has Supernus Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- Supernus Pharmaceuticals's unrealized losses on investments (before tax) increased by 46.8% year-over-year, from $173K to $254K.
- What is the long-term trend for Supernus Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -8.0% compound annual growth rate (CAGR), from $41K to $27K.